scholarly journals Leiomyosarcoma of the inferior vena cava with renal metastasis: An unusual case and diagnostic challenge

2014 ◽  
Vol 8 (9-10) ◽  
pp. 358
Author(s):  
Garson Chan ◽  
Tadeusz Kroczak ◽  
Darrel Drachenberg

Leiomyosarcomas are exceedingly rare malignant tumours with a very poor prognosis. We present a 78-year-old patient with a small renal and paracaval mass. Surgery included right open partial nephrectomy and resection of the paracaval mass to treat the presumed renal cell carcinoma. Pathology revealed the tumour tobe leiomyosarcoma (LMS). This is only the second documented report of an inferior vena cava LMS presenting along with an ipsilateral renal mass.

2018 ◽  
Vol 57 (17) ◽  
pp. 2517-2521
Author(s):  
Junichi Imanishi ◽  
Michiko Iseri ◽  
Masahiro Motoki ◽  
Sachiko Yoshikawa ◽  
Naohiko Sone ◽  
...  

2017 ◽  
Vol 3 ◽  
pp. 92-92
Author(s):  
Firas Emad Abu Akar ◽  
Chenlu Yang ◽  
Yiming Zhou ◽  
Lei Lin ◽  
Diego Gonzalez-Rivas ◽  
...  

2019 ◽  
Vol 15 (4) ◽  
pp. 673-678
Author(s):  
Luisella Perina ◽  
Giacomo Marchi ◽  
Fabiana Busti ◽  
Giacomo Avesani ◽  
Alice Parisi ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e16080-e16080
Author(s):  
Suguru Oka ◽  
Naoko Inoshita ◽  
Yuji Miura ◽  
Ryosuke Oki ◽  
Yu Miyama ◽  
...  

e16080 Background: Renal cell carcinoma (RCC) is characterized by a propensity for extension into the renal vein and inferior vena cava (IVC), and affected patients have a poor prognosis. BAP1 mutation, which occurs in about 15% of patients with clear cell RCC (ccRCC), also predicts a poor prognosis. The aim of this study was to elucidate the association between BAP1 expression and clinicopathologic outcomes in patients with ccRCC with an IVC tumor thrombus. Methods: Thirty-nine patients with ccRCC with an IVC tumor thrombus who underwent radical nephrectomy and tumor thrombectomy at our institution from 1999 to 2010 were retrospectively evaluated. Immunohistochemical analyses were performed for the expression of BAP1, and the associations between the expression of BAP1 and clinical outcomes were assessed. Survival analyses were performed using the Kaplan–Meier method and log-rank test. Multivariate analyses of the associations between overall survival (OS) and clinical variables were performed using a Cox proportional hazard model. For all analyses, P < 0.05 was considered statistically significant. Results: The median follow-up time was 58.8 months (range, 2–130 months). The median age was 66 years (range, 37–80 years). Four patients (10.3%) had lung metastasis at the initial diagnosis. The primary tumor was right-sided in 27 (69.2%) patients and left-sided in 12 (30.8%). The IVC tumor thrombus extended above and below the diaphragm in 11 (28.2%) and 28 (71.8%) patients, respectively. The KPS score was > 80 in 23 patients (59.0%). BAP1 expression was positive in 26 (67.0%) cases and negative in 13 (33.0%). BAP1-negative tumors were associated with a significantly shorter OS than BAP1-positive tumors (median OS, 42.0 vs. 81.5 months, respectively; P = 0.019). The median disease-free survival in BAP1-negative and -positive tumors was 10.0 and 19.0 months, respectively (P = 0.019). Multivariate analysis showed that only a BAP1-negative status was significantly associated with shorter OS (P = 0.026). Conclusions: A BAP1-negative tumor status was significantly associated with a poor prognosis in patients with ccRCC with an IVC tumor thrombus who underwent radical nephrectomy and tumor thrombectomy.


2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 229-229
Author(s):  
A. Heidenreich ◽  
M. Schrader ◽  
K. Dieckmann ◽  
C. Winter ◽  
D. A. Pfister ◽  
...  

229 Background: PC-RPLND remains an integral part of the multimodality treatment for advanced NSGCT. The need to resect and to replace the major retroperitoneal vessels must be known preoperatively to enable complete resection of the residual masses. Methods: PC-RPLND was performed in 411 patients with NSGCT and normalized (81%) or plateauing (19%) tumor markers following 3-4 cycles PEB/PEI. PC-RPLND was performed in 5 institutions with a variable surgical frequency of 14 to 158 PC-RPLNDs. Good, intermediate, and poor prognosis according to the IGCCCG criteria was identified in in 59.8%, 21.2%, and 19% respectively. Results: Resection of the inferior vena cava was performed in 28 (6.81%), resection of the abdominal aorta was necessary in 13 (3.16%) patients. In 29/41 (70.7%) adjunctive surgical procedures such as nephrectomy, small bowel resection, ureteral resection had to be performed to ensure complete resection of the residual masses. Histologically vital cancer or mature teratoma was identified in 78.1% of the resected vascular specimens. Mean time of surgery was 295 (243-615) Min., mean blood loss was 690 (350 – 3400) ml. Good prognosis was identified in 15.4%, intermediate and poor prognosis was present in 41%and 43.6%, resp. Of all 411 patients involvement of the major retroperitoneal vessels was found in 3.2%, 18.4% and 21.8% with good, intermediate, and poor prognosis, resp. The mean tumor diameter was 5.9 (1.0 – 32) cm for the entire cohort and 9.8 (4-32) cm for the cohort of patients with vascular surgery. Significant prognosticators to predict vascular involvement were identified by multivariate analysis: intermediate/poor prognosis, number of cycles of chemotherapy, tumor diameter > 14cm, circumferential encasement of > 50% of the vessel diameter. Conclusions: Complete resection of the inferior vena cava or the abdominal aorta during PC-RPLND is necessary in about 10% of patients. The identified predictors enable already preoperatively a risk adapted interdisciplinary approach for complete resection of the residual masses in an experienced centre. No significant financial relationships to disclose.


2014 ◽  
Vol 36 (7) ◽  
pp. 583-585 ◽  
Author(s):  
José L. Unzueta-Roch ◽  
Miriam García-Abós ◽  
Sara Sirvent-Cerdá ◽  
Inmaculada de Prada ◽  
Amelia Martínez de Azagra ◽  
...  

2013 ◽  
Vol 45 (3) ◽  
pp. 537-543 ◽  
Author(s):  
Dominique Fabre ◽  
Rabih Houballah ◽  
Elie Fadel ◽  
Petru Bucur ◽  
Charles Bakhos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document